Persistent tumor cells in bone marrow of non-metastatic breast cancer patients after primary surgery are associated with inferior outcome
暂无分享,去创建一个
J. Reuben | J. T. Kvaløy | O. Nordgård | Satu Oltedal | K. Tjensvoll | B. Gilje | R. Heikkilä | R. Smaaland | J. Kvaløy
[1] W. Woodward,et al. Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44⁺CD24lo cancer stem cell phenotype. , 2011, European Journal of Cancer.
[2] T. Fehm,et al. Persistence of Disseminated Tumor Cells in the Bone Marrow of Breast Cancer Patients Predicts Increased Risk for Relapse—A European Pooled Analysis , 2011, Clinical Cancer Research.
[3] F. Shammas,et al. Disseminated tumor cells in bone marrow assessed by TWIST1, cytokeratin 19, and mammaglobin A mRNA predict clinical outcome in operable breast cancer patients. , 2010, Clinical breast cancer.
[4] W. Gianni,et al. Cancer stem cells and epithelial-mesenchymal transition: revisiting minimal residual disease. , 2010, Current cancer drug targets.
[5] P. V. van Dam,et al. Circulating tumour cell detection: a direct comparison between the CellSearch System, the AdnaTest and CK-19/mammaglobin RT–PCR in patients with metastatic breast cancer , 2009, British Journal of Cancer.
[6] S. Agelaki,et al. Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer , 2009, British Journal of Cancer.
[7] Jan Terje Kvaløy,et al. A small subgroup of operable breast cancer patients with poor prognosis identified by quantitative real-time RT-PCR detection of mammaglobin A and trefoil factor 1 mRNA expression in bone marrow , 2009, Breast Cancer Research and Treatment.
[8] G. Kallergi,et al. Prognostic Value of the Molecular Detection of Circulating Tumor Cells Using a Multimarker Reverse Transcription-PCR Assay for Cytokeratin 19, Mammaglobin A, and HER2 in Early Breast Cancer , 2008, Clinical Cancer Research.
[9] T. Kroll,et al. Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] F. Shammas,et al. Bone marrow cytokeratin 19 mRNA level is an independent predictor of relapse-free survival in operable breast cancer patients , 2008, Breast Cancer Research and Treatment.
[11] R. Bast,et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] A. Giuliano,et al. Most Early Disseminated Cancer Cells Detected in Bone Marrow of Breast Cancer Patients Have a Putative Breast Cancer Stem Cell Phenotype , 2006, Clinical Cancer Research.
[13] T. Fehm,et al. A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation , 2006, Cancer.
[14] T. Fehm,et al. Detection of cytokeratin-positive cells in the bone marrow of breast cancer patients undergoing adjuvant therapy , 2006, Breast Cancer Research and Treatment.
[15] J. Nesland,et al. Comparison of the clinical significance of occult tumor cells in blood and bone marrow in breast cancer , 2006, International journal of cancer.
[16] P. Dam,et al. Real time RT-PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer , 2006 .
[17] E. van Marck,et al. Real-time RT–PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer , 2006, British Journal of Cancer.
[18] Douglas G Altman,et al. Reporting recommendations for tumor marker prognostic studies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] T. Fehm,et al. A pooled analysis of bone marrow micrometastasis in breast cancer. , 2005, The New England journal of medicine.
[20] Takuji Tanaka,et al. An evaluation of the integration of non-traditional learning tools into a community based breast and cervical cancer education program: The witness project of Buffalo , 2003, BMC Cancer.
[21] K. Pantel,et al. Circulating Tumor Cells in Breast Cancer: Correlation to Bone Marrow Micrometastases, Heterogeneous Response to Systemic Therapy and Low Proliferative Activity , 2005, Clinical Cancer Research.
[22] Michael Dean,et al. Tumour stem cells and drug resistance , 2005, Nature Reviews Cancer.
[23] H. Graham,et al. Persistence of bone marrow micrometastases in patients receiving adjuvant therapy for breast cancer: Results at 4 years , 2005, International journal of cancer.
[24] S. Braun,et al. The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence , 2005, Cancer.
[25] J. Nesland,et al. Isolated Tumor Cells in Bone Marrow Three Years after Diagnosis in Disease-Free Breast Cancer Patients Predict Unfavorable Clinical Outcome1 , 2004, Clinical Cancer Research.
[26] J. Nesland,et al. The Prognostic Value of Isolated Tumor Cells in Bone Marrow in Breast Cancer Patients , 2004, Clinical Cancer Research.
[27] G Kvalheim,et al. Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] S. Braun,et al. The fate and prognostic value of occult metastatic cells in the bone marrow of patients with breast carcinoma between primary treatment and recurrence , 2001, Cancer.
[29] T. Dimpfl,et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. , 2000, The New England journal of medicine.
[30] J. V. Van eekelen,et al. Sensitive and quantitative one-step polymerase chain reaction using capillary electrophoresis and fluorescence detection for measuring cytokeratin 19 expression. , 1999, Scandinavian journal of clinical and laboratory investigation.
[31] S. Braun,et al. Re: Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. , 1996, Journal of the National Cancer Institute.
[32] K. Pantel,et al. Cancer micrometastases , 2009, Nature Reviews Clinical Oncology.
[33] R. Holle,et al. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. , 1996, Journal of the National Cancer Institute.